Fox Run Management L.L.C. Has $221,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Fox Run Management L.L.C. has reduced its stake in BioCryst Pharmaceuticals (BCRX) by 56.8%, now holding 29,425 shares valued at approximately $221,000.
• Director Theresa Heggie sold 70,000 shares of BioCryst stock for about $595,700, resulting in a 51.72% decrease in her holdings.
• Analysts have a consensus rating of "Moderate Buy" for BCRX, with an average price target of $16.70.

Fox Run Management L.L.C. cut its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 56.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 29,425 shares of the biotechnology company's stock after selling 38,615 shares during the quarter. Fox Run Management L.L.C.'s holdings in BioCryst Pharmaceuticals were worth $221,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BCRX. Wells Fargo & Company MN raised its position in shares of BioCryst Pharmaceuticals by 53.2% during the 4th quarter. Wells Fargo & Company MN now owns 104,163 shares of the biotechnology company's stock worth $783,000 after buying an additional 36,166 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of BioCryst Pharmaceuticals by 86.1% during the 4th quarter. Russell Investments Group Ltd. now owns 27,966 shares of the biotechnology company's stock worth $210,000 after buying an additional 12,941 shares in the last quarter. Invesco Ltd. raised its position in shares of BioCryst Pharmaceuticals by 6.7% during the 4th quarter. Invesco Ltd. now owns 1,072,600 shares of the biotechnology company's stock worth $8,066,000 after buying an additional 67,492 shares in the last quarter. Legal & General Group Plc raised its position in shares of BioCryst Pharmaceuticals by 3.9% during the 4th quarter. Legal & General Group Plc now owns 275,083 shares of the biotechnology company's stock worth $2,069,000 after buying an additional 10,199 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $80,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 2.4%

Shares of BioCryst Pharmaceuticals stock traded down $0.2050 during trading on Monday, hitting $8.3550. The stock had a trading volume of 876,454 shares, compared to its average volume of 3,773,277. The company has a market capitalization of $1.75 billion, a PE ratio of -46.41, a P/E/G ratio of 1.94 and a beta of 1.10. The stock has a 50 day simple moving average of $8.83 and a 200 day simple moving average of $8.79. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.01 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. The business's revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.06) earnings per share. As a group, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BCRX. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Needham & Company LLC reaffirmed a "buy" rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Wedbush lifted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research note on Monday, June 30th. Finally, Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.70.

Insider Activity at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.10% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.